Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia

NCT01658956 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01658956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01658956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2012
Completion date
July 31, 2015
Enrollment
142 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer